The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-in-human phase 1 dose escalation trial of OMTX705, a novel anti-fibroblast activation protein (FAP) antibody drug conjugate (ADC), in monotherapy and in combination with pembrolizumab in patients with solid tumors.
 
Javier Torres-Jiménez
No Relationships to Disclose
 
Ana Paisan
Speakers' Bureau - Daiichi Sankyo Europe GmbH; Novartis
 
Mariano Ponz-Sarvise
Consulting or Advisory Role - Ability Pharma; AstraZeneca Spain; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Novocure (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - AstraZeneca (Inst); Incyte; Oncosil
 
Bruno Bockorny
Honoraria - BiolineRx; Enlivex Therapeutics Ltd
Consulting or Advisory Role - Blueprint Medicines
Research Funding - Agenus (Inst); Nanoview Diagnostics
Travel, Accommodations, Expenses - Agenus; ERYTECH Pharma
 
Marta Gil-Martin
Consulting or Advisory Role - AstraZeneca
Speakers' Bureau - Eisai; GlaxoSmithKline; MSD Oncology
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline; MSD Oncology
 
Ricardo Cubedo
Employment - HOSPITEN
 
Luis Paz-Ares
Leadership - ALTUM Sequencing; Stab Therapeutics
Stock and Other Ownership Interests - Altum Sequencing; Stab therapeutics
Honoraria - Abbvie; Amgen; AstraZeneca; Bayer; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Gilead Sciences; GlaxoSmithKline; Janssen; Lilly; Medscape; Merck Serono; MSD; Novartis; Pfizer; PharmaMar; Regeneron; Roche/Genentech; Sanofi; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; AstraZeneca; AstraZeneca; Bayer; BMS; GlaxoSmithKline; Janssen; Lilly; Merck; Mirati Therapeutics; MSD; Novartis; Pfizer; Pharmamar; Regeneron; Roche; Sanofi; Takeda
Speakers' Bureau - Amgen; AstraZeneca; BeiGene; BMS; Daiichi Sankyo Europe GmbH; Lilly; Merck Serono; MSD Oncology; Pfizer; Roche/Genentech
Research Funding - AstraZeneca (Inst); BMS (Inst); MSD (Inst); Pfizer (Inst); PharmaMar (Inst)
Other Relationship - Amgen (I); Astellas Pharma (I); Crinetics Pharmaceuticals (I); Esteve (I); HUTCHMED (I); Ipsen (I); ITM Isotope Technologies Munich (I); Merck (I); Novartis (I); Pfizer (I); Roche; Roche (I); Sanofi (I); SERVIER (I)
 
Ana Landa-Magdalena
Travel, Accommodations, Expenses - AstraZeneca; Incyte; Incyte; Merck; MSD Oncology; Roche
 
Gerburg Wulf
Stock and Other Ownership Interests - Selecta Biosciences (I)
Consulting or Advisory Role - Totus Medicines
Research Funding - Boundless Bio (Inst); Celgene (Inst); Gilead Sciences (Inst); Mersana (Inst); Pfizer (Inst); PureTech (Inst); PureTech (Inst); PureTech (Inst); PureTech (Inst); Seagen (Inst); Totus Medicines (Inst)
Patents, Royalties, Other Intellectual Property - Pin1 as a marker for abnormal cell growth Patent number: 8129131; Pin1 inhibitors (Inst)
 
Paula Sàbat
Travel, Accommodations, Expenses - Gilead Sciences
Other Relationship - Lilly
 
Fabio Franco Perez
No Relationships to Disclose
 
Myriam Fabre
Employment - Oncomatryx
Stock and Other Ownership Interests - Oncomatryx
Research Funding - Oncomatryx
Patents, Royalties, Other Intellectual Property - Oncomatryx
 
Alvaro Gonzalez
Employment - Oncomatryx
 
Patricia Gonzalez
Employment - Oncomatryx
 
Isabel Egaña
Employment - Oncomatryx
 
Susana Roman
Employment - Oncomatryx
 
Laureano Simon
Employment - Oncomatryx; Patia Biopharm; Quimatryx Biopharm
Leadership - Oncomatryx; Patia Biopharm; Quimatrix Biopharm; SunRock Biopharma
Stock and Other Ownership Interests - Helenes Ventures; Nelum Corp.; Oncomatryx; Patia Biopharm; Permedika entrepeneurs; SunRock Biopharma
Patents, Royalties, Other Intellectual Property - Oncomatryx; Patia Biopharm; Quimatryx
 
Ignacio Garcia-Ribas
Employment - Oncomatryx
Stock and Other Ownership Interests - Oncomatryx; Sanofi
Consulting or Advisory Role - Cantargia AB; Exscientia; Optimapharm; Shionogi; TFS; Zumutor Biologics
Patents, Royalties, Other Intellectual Property - Oncomatryx
 
Ander Urruticoechea
Consulting or Advisory Role - Ellipses Pharma; InProTher
Travel, Accommodations, Expenses - AstraZeneca Spain; Gilead Sciences; Novartis; Pfizer; Pierre Fabre; Roche